Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $3.75

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned a consensus rating of “Hold” from the seven brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $3.75.

HOWL has been the subject of several analyst reports. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $0.36 on Friday. The stock’s fifty day moving average is $0.39 and its 200 day moving average is $0.61. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.38. The firm has a market capitalization of $17.51 million, a PE ratio of -0.29 and a beta of 0.30.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Equities analysts forecast that Werewolf Therapeutics will post -1.08 EPS for the current year.

Insider Activity at Werewolf Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total transaction of $145,918.85. Following the transaction, the insider owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. This represents a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Luke Evnin sold 305,741 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the sale, the director owned 1,273,008 shares in the company, valued at approximately $891,105.60. The trade was a 19.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,067,237 shares of company stock valued at $2,070,189 in the last 90 days. Company insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Regal Investment Advisors LLC lifted its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth about $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC lifted its holdings in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.